Person: KOCAKAYA, DERYA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KOCAKAYA
First Name
DERYA
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication Metadata only Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?(2022-09-01) VEZİR, DUYGU; KOCAKAYA, DERYA; MERCANCI, ZEYNEP; KARAKURT, SAİT; Vezir D., Yildizeli S. O., KOCAKAYA D., Mercanci Z., Balcan B., Cinar C., Eryuksel E., KARAKURT S.Publication Metadata only The predictive role of psychological status and disease severity indexes on quality of life among patients with non-CF bronchiectasis(2022-01-01) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; ERYÜKSEL, SEMİHA EMEL; CEYHAN, BERRİN; CEYHAN B., Bekir M., KOCAKAYA D., OLGUN YILDIZELİ Ş., ERYÜKSEL S. E.OBJECTIVE: Bronchiectasis is a chronic suppurative lung disease that significantly impacts the patients\" quality of life. The aim of this study is to evaluate the relationship between quality of life and patient\"s psychological status and bronchiectasis disease severity indexes in patients with non-cystic fibrosis bronchiectasis. We also aimed to investigate the validity and reliability of Turkish version of Quality of Life Questionnaire-Bronchiectasis (V3.1) in Turkish adult bronchiectatic patients.Publication Metadata only Late breaking abstract - association with changes in pulmonary artery diameters and outcomes before, during and after covid-19 hospitalization: Retrospective study(2023-09-09) KOCAKAYA, DERYA; Selcuk A., Kocakaya D., Olgun Yildizeli Ş., Karakurt S.Background:Enlarged main pulmonary artery diameter(MPAD)is a predictor of increased mortality in COVID-19. However, the changes in MPAD before and after COVID-19 remain obscure.Aim:To find the factors that affect changes in MPAD during COVID-19 and postCOVID-19 period; the relationship between the MPAD, thromboinflammation and radiological scores(RS), clinical outcomes in patients.Methods:This study is retrospective and single centered. Among the 3264 patients hospitalized followed at least 3 months between March 2020 and January 2023, 66 patients with previous and subsequent chest CT were included.3 measurements of MPAD before, during and after COVID-19, WHO Score, RS and laboratory variables have been recorded from the hospital information system. ICU admission and mortality as clinical outcomes and factors that affect MPAD evaluated by uni-and multivariate analysis.Results:MPAD of patients had increased during COVID-19 and showed tendency to decrease but persisted to increase after(p<0.001,p>0.05). Low Lymphocyte/CRP, high D-dimer and ICU admission had significantly increased risk for remained enlarged MPAD postCOVID-19(OR=10.37,p<0.01;OR=1.1, p<0.01,OR=5.14, p<0.01). Patient with higher postMPAD had significant correlation with increased WHO Score and RS after COVID-19(both R=0.3,p<0.05)but not mortality.Conclusion:MPAD significantly increases during COVID-19 and persisted after that. Apart from that, patients who admitted to ICU, had high d-dimer and inflammation markers in COVID-19,had increased risk for enlarged postMPAD that correlated WHO-Score and radiological scores in post-COVID-19. Especially these patients, can be followed carefully after the infection.Publication Metadata only The effects of iron replacement on functional capacity in patients with group 1 and group 4 pulmonary hypertension(2022-10-01) ATAŞ, HALİL; KOCAKAYA, DERYA; YILDIZELİ, BEDRETTİN; MUTLU, BÜLENT; Akaslan D., Aslanger E., ATAŞ H., Kanar B. G. , KOCAKAYA D., YILDIZELİ B., MUTLU B.Objective: Abnormal iron handling complicates pulmonary hypertension and causes functional limitation and poor outcomes. Although preliminary results in group 1 pulmonary hypertension patients support the use of iron replacement, whether this applies to other PH subgroups is not known.Publication Metadata only Pulmoner arter sarkomanın cerrahi sonuçları: Histoloji sağkalımı etkiler mi(2023-08-01) BOZKURTLAR, EMİNE; OLGUN YILDIZELİ, ŞEHNAZ; MUTLU, BÜLENT; KOCAKAYA, DERYA; BEKİROĞLU, GÜLNAZ NURAL; YILDIZELİ, BEDRETTİN; Başar V., Olgun Yıldızeli Ş., Bozkurtlar E., Ercelep ., Mutlu B., Kocakaya D., Bekiroğlu G. N., Taş S., Sunar H., Küçükoğlu M. S., et al.Publication Metadata only Is the risk of tuberculosis increased in behcet's disease compared to other rheumatological disorders after anti-tnf-a treatment(2019-03-01) GAZEL, ÜMMÜGÜLSÜM; KOCAKAYA, DERYA; KARABACAK, MURAT; ATAGÜNDÜZ, MEHMET PAMİR; ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; Gazel U., KOCAKAYA D., Topcu I., Karatas H., Karabacak M., ATAGÜNDÜZ M. P. , Inanc N., Alibaz-Oner F., DİRESKENELİ R. H.Publication Metadata only Isolated pulmonary vasculitis diagnosed histopathologically after pulmonary endarterectomy: a case series(2019-03-01) GAZEL, ÜMMÜGÜLSÜM; KOCAKAYA, DERYA; YILDIZELİ, BEDRETTİN; ALİBAZ ÖNER, FATMA; DİRESKENELİ, RAFİ HANER; Gazel U., KOCAKAYA D., Salcinkaya Y., Inanc N., YILDIZELİ B., Alibaz-Oner F., DİRESKENELİ R. H.Publication Metadata only Obstructive Sleep Apnea in patients with Cystic Fibrosis and non-Cystic Fibrosis Bronchiectasis and its relation with clinical parameters(2022-09-01) VEZİR, DUYGU; KOCAKAYA, DERYA; CEYHAN, BERRİN; Vezir D., Balcan B., KOCAKAYA D., Cinar C., Olgun S., CEYHAN B.Objective: This study was designed to assess obstructive sleep apnea (OSA) in adult patients with cystic fibrosis (CF) and non-CF bronchiectasis (BE) and to relate it with clinical characters. Methods: 35 CF (27yrs) and 35 non-CF (24yrs) BE patients were included. Demographic characteristics, medications, comorbidities, BMI, dyspnea scales, pulmonary functions, sputum cultures, exacerbations, and hospitalizations were recorded. Epworth Sleepiness Scale (ESS) questionnaire was filled and polysomnography was performed for each patient. Results: ESS scores did not show any significant difference between CF and non-CF BE patients. 37 (53%) of all patients had OSA. There was no significant difference for OSA risk between CF and non-CF BE patients (54% vs 51%, respectively). Male gender was found to be a risk factor for OSA (68% of males vs 41% of females, respectively, p:0.026). Total sleep time, sleep efficiency, sleep latency, time spent awake after falling asleep, ODI, AHI, AHI in supine position and REM phase did not show any significant difference between CF and non-CF patients. CF patients had significantly lower mean oxygen saturation (p:0.001) and lowest oxygen saturation (p:0.0024) levels and higher heart rate (p:0.02) compared to non-CF BE patients. Multiple logistic regression analysis of all patients revealed male gender and disease duration as risk factors for OSA (p:0.023 and p:0.041 respectively).Publication Metadata only Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic(2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.Publication Metadata only Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients(2023-05-31) MERCANCI, ZEYNEP; ILGIN, CAN; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; BALCAN, MEHMET BARAN; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; Mercanci Z., ILGIN C., Yildizeli S. O., KOCAKAYA D., Balcan B., Sengel B. E., KARAKURT S., Eryuksel E.Objective: Coagulopathy is thought to play an important role in the development of severe COVID-19. High D-dimer levels have been reported in Chinese cohort studies. However, ethnicity has significant implications for thrombotic risk. Our aim in this study is to determine the effect of D-dimer measurements on disease prognosis and mortality in Turkish patients with COVID-19. Patients and Methods: The study was designed retrospectively. Patients over the age of 18 who were admitted to our hospital were included in the study. Results: The study included 226 patients. According to the World Health Organization staging, 75(33.2%) patients, according to the staging of Siddiqi et al., 67 (29.7%) patients progressed. In the ROC analysis performed to predict mortality, AUC value for D-dimer was found to be 82.25% (95%CI 74.8%-89.71%). When the cut-off value for D-dimer was accepted as ≥3.25mg/L, specificity was 94.15%, correctly classified rate 88.5%, positive likelihood ratio as (LR):5.69, negative LR:0.71. Conclusion: As a result, similar to the Chinese cohorts, elevated D-dimer measurements increase disease progression and mortality in Turkish patients with COVID-19. D-dimer levels of 3.25 mg/L and above, strongly determine the risk of increased mortality in the Turkish Caucasian ethnic group.